



**Dr. Masaru Shimizu Presents Multi-Center Clinical Trial Results for  
ThermoGenesis CryoSeal® FS System in Japan**

*Excellent Performance and Safety during  
Surgical Procedures*

**RANCHO CORDOVA, California (October 18, 2005) – ThermoGenesis Corp. (NASDAQ: KOOL)** announced today that Dr. Masaru Shimizu, Professor of Kyorin University School of Medicine, and principal investigator for the pivotal clinical trial to test the ability of CryoSeal “autologous” fibrin sealant to arrest bleeding in cardiovascular, orthopedic, neurosurgery and esophageal surgery patients presented his data at the American Association of Blood Banks conference in Seattle, Washington on October 16, 2005. The 72-patient trial, conducted at six clinical sites, included 17 – 20 cases for each of the four surgical fields. Dr. Shimizu’s presentation ended with these conclusions:

- An average of  $5.1 \pm 1.2$  mL (77 samples) of cryoprecipitate and an equal amount of thrombin solution were produced from 200-400 mL of plasma.
- The average concentration of fibrinogen in the cryoprecipitate produced was  $2,350 \pm 702$  mg/dL (N=71) and average thrombin activity  $30.1 \pm 10.9$  U/ml (N=71). In the clinical trial, the clinical efficacy rate (effective or better) was 90.3% (65/72 subjects) and no adverse events were seen that were causally related to the trial device.
- The completely autologous fibrin sealant prepared by the CryoSeal was shown to be safe and to have excellent performances.

Asahi Kasei Medical Co. Ltd., exclusive distributor of the CryoSeal System in Japan, filed a Pre-Market Approval (PMA) submission with this clinical data in March 2005. The fibrin sealant market in Japan is currently estimated at \$130 million/year.

Philip Coelho, CEO of ThermoGenesis commented, “This is a key milestone in the development of the CryoSeal FS System as a new safe alternative source of surgical sealant for Japan, the world’s largest market for conventional fibrin sealants. We recently concluded our U.S. clinical trial enrollment this past June and plan to submit our U.S. PMA for approval by the end of this calendar year. Conventional fibrin sealants are produced from ‘pooled collections’ of thousands of units of purchased human blood plasma and bovine blood or lung tissue. Recent reports in Japanese medical journals have identified these ‘pooled’ products as the source of parvovirus B19 transmission to patients which is a cause of hemolytic anemia.”

**Regulatory Status**

ThermoGenesis Corp. has received a right to affix the CE Mark to the CryoSeal FS System from its European Notified Body. In Japan, Asahi Kasei Medical, who is the

Japanese distributor, has completed their PMA submission to the MHLW. A 150-patient, blinded multi-center Phase III clinical trial of CryoSeal FS System has completed enrollment in the United States and a PMA submission is being prepared.

**About Asahi Kasei Medical Co., Ltd.**

Asahi Kasei Medical Co., Ltd. is a world leader in research, development, production and sales of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with dialysis products, plasma therapy products, and blood transfusion products for medical therapy all over the world.

**About ThermoGenesis Corp.**

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood.

- The **BioArchive® System**, an automated robotic cryogenic device, is used by major cord blood stem cell banks in 26 countries as a key enabling technology for cryopreserving and archiving stem cell units for transplant.
- The **AutoXpress™ System**, currently undergoing Alpha testing, is a semi-automated robotic device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood.
- The **CryoSeal FS System**, a semi-automated device and companion sterile blood processing disposable, is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour. Enrollment in a 150 patient U.S. pivotal clinical trial has been completed and a PMA is being prepared.
- The **Thrombin Processing Device (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of patient blood, or blood plasma in 25 minutes. The TPD market launch is underway in Europe.

*The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.*

**More Information, Contact:**  
**THERMOGENESIS CORP.**  
Philip Coelho: (916) 858-5100